Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Cynata Therapeutics is an Australian clinical-stage biotechnology company developing Cymerus™, a proprietary mesenchymal stem cell (MSC) technology platform that generates therapeutic-grade stem cells from induced pluripotent stem cells (iPSCs). The company is advancing multiple clinical programs including CYP-004 for respiratory conditions (COVID-19, asthma) and CYP-006 for osteoarthritis, with partnerships including Fujifilm for manufacturing and various regional licensing agreements. As a pre-revenue biotech, the stock trades on clinical trial milestones, regulatory progress, and cash runway management.
Cynata's business model centers on developing off-the-shelf allogeneic MSC therapies that avoid patient-specific manufacturing, potentially offering significant cost advantages versus autologous cell therapies. The Cymerus platform enables scalable, consistent production from a single iPSC master cell bank, targeting a manufacturing cost structure estimated at $5,000-$15,000 per dose versus $50,000+ for competitor autologous approaches. Revenue generation depends on successfully navigating Phase 2/3 trials, securing regulatory approvals, and either commercializing directly in select markets or licensing to larger pharmaceutical partners. The company has established manufacturing partnerships with Fujifilm to de-risk production scale-up. Pricing power will depend on demonstrating superior efficacy or cost-effectiveness versus existing treatments in target indications.
Clinical trial data readouts for CYP-004 (respiratory) and CYP-006 (osteoarthritis) programs - positive efficacy/safety results typically drive 30-100% single-day moves
Regulatory milestone achievements including IND approvals, Fast Track designations, or breakthrough therapy status from FDA/EMA/TGA
Partnership announcements or licensing deals with major pharmaceutical companies that provide validation and non-dilutive funding
Capital raises and cash runway updates - dilutive financings typically pressure stock 20-40% while strategic investments provide support
Competitive developments in MSC therapy space including approvals or failures of rival programs from Mesoblast, Athersys, or Pluristem
Clinical trial failure risk - Phase 2/3 programs carry 60-70% historical failure rates in cell therapy; single negative readout could eliminate 70-90% of market value
Regulatory pathway uncertainty for novel cell therapies - FDA/EMA frameworks for allogeneic MSC products remain evolving with inconsistent approval standards across jurisdictions
Manufacturing scalability and CMC challenges - cell therapy production faces quality control, contamination, and consistency risks that have derailed competitor programs
Reimbursement uncertainty - even with approval, payer willingness to cover high-cost cell therapies remains unproven outside oncology indications
Mesoblast (MESO) advancing competing allogeneic MSC programs with larger capital base and more advanced clinical pipeline including approved products in Japan
Established pharmaceutical companies developing small molecule or biologic alternatives for target indications (osteoarthritis, respiratory) with lower manufacturing complexity
Academic institutions and well-funded startups pursuing next-generation iPSC-derived cell therapies with potentially superior differentiation protocols
Cash runway risk - current burn rate of $8-12M annually against estimated cash position requires capital raise within 12-18 months, likely at dilutive terms given pre-revenue status
Equity dilution risk - company has raised capital through share issuances historically; additional raises at current $100M market cap could dilute existing shareholders 30-50%
Going concern risk if unable to secure financing - failure to raise capital or achieve partnership milestones could force asset sales or wind-down
low - Pre-revenue biotech companies exhibit minimal direct correlation to GDP or consumer spending as they operate in capital markets-driven funding cycles rather than commercial revenue cycles. However, risk appetite for speculative growth assets does correlate with broader economic confidence, affecting ability to raise capital on favorable terms.
High sensitivity to interest rates through multiple channels: (1) Valuation impact - biotech stocks trade on discounted future cash flows, making them highly sensitive to discount rate changes; rising rates from current levels compress NPV of distant commercialization scenarios by 20-40%. (2) Funding environment - higher rates reduce venture capital and institutional appetite for cash-burning growth stories, tightening capital availability. (3) Opportunity cost - rising risk-free rates make speculative biotech less attractive versus bonds. The 2022-2024 rate hiking cycle compressed biotech valuations 50-70% sector-wide.
Minimal direct credit exposure as company carries no debt (Debt/Equity: 0.00) and operates on equity financing. However, indirectly exposed to credit conditions through: (1) Biotech sector funding availability - credit tightening reduces institutional risk appetite for equity raises. (2) Partnership economics - pharmaceutical partners' willingness to pursue licensing deals correlates with their own financing costs and M&A capacity.
growth/speculative - Attracts high-risk tolerance investors seeking asymmetric returns from clinical-stage biotech binary events. Typical holders include specialized healthcare hedge funds, biotech-focused venture investors, and retail traders pursuing momentum on trial catalysts. Not suitable for value or income investors given negative earnings, no dividends, and binary risk profile. Recent 86% six-month return indicates momentum/speculative interest.
high - Clinical-stage biotech stocks routinely exhibit 30-50% intraday moves on trial data, with annualized volatility typically 80-120%. Small market cap ($100M) and limited liquidity amplify price swings. Beta to broader market likely 1.5-2.0x but with idiosyncratic risk dominating systematic risk.
